Supplementary Tables 1 and 2 and Supplementary Figures 1 through 7 from Evaluation of Apoptosis Induction by Concomitant Inhibition of MEK, mTOR, and Bcl-2 in Human Acute Myelogenous Leukemia Cells

PDF - 495K, Supplementary Table 1: Gene Alterations in AML Cell Lines used in This Study Supplementary table 52:Gene alterations and cytogenetic information on 10 periphoral blood or bone marrow samples obtained from AML patients Fig. S1. Molecular structures of drugs used in this study. Fig. S2. The Chou-Talalay method Chou et al. Cancer Res. 2010; 70: 440-446 was used to determine combination indices (CIs) in AML cell lines treated with combination of AZD8055 and selumetinib for 48 hours. Fig. S3. OCI/AML3 cells were pretreated with proteasome inhibitors bortezemib (0.01 micromol/L) or MG132 (0.5 micromol/L) for 2 hours following by combination of AZD8055 (0.4 micromol/L) and selumetinib (0.2 micromol/L) for additional 48 hours. The apoptosis induction was measured using flow cytometry. Fig. S4. U937 cells were electroporated with Bim siRNA or scrambled siRNA for 24 hours, treated with AZD8055 (0.4 micromol/L) and/or selumetinib (0.2 micromol/L) for 48 hours, and examined for apoptosis induction. Inset: knockdown of basal level of Bim protein expression. Fig. S5. AML cells were treated with indicated doses of selumetinib for 48 hours and apoptosis induction was determined using flow cytometry by measuring percentage of Annexin V positivity. Fig. S6. AML cells were treated with indicated doses of AZD8055 for 48 hours and apoptosis induction was determined using flow cytometry by measuring percentage of Annexin V positivity. Fig. S7. OCI/AMl3_shGFP and OCI/AMl3_shMcl-1 AML cells were treated with indicated doses of ABT-737 for 48 hours and apoptosis induction was determined using flow cytometry by measuring Annexin Vneg/PIneg population.